NSE filing, NSE: APOLLO. Summary written from the filing by ALFA Finder's alert engine.
Apollo Micro Systems Ltd: key numbers
- Share price
- ₹414.90
- Market cap
- ₹14,825 Cr
- Revenue (annual)
- ₹904.3 Cr
- Net profit (annual)
- ₹112.9 Cr
- P/E (TTM)
- 106.9×Sector 52.2×
- Promoter holding
- 49.98%+0.00% QoQ
- FII holding
- 5.95%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Apollo Micro Systems Ltd
All →Apollo Micro Systems Earnings Call Transcript: Key Takeaways
Apollo reported record-breaking performance driven by defense indigenization, yet consolidated margins are temporarily dampened by the transition of loss-making subsidiary Ideal Explosives.
- Call
- Guides 45% growth
Apollo Micro Systems Business Update
Apollo Micro Systems' MD issued a shareholder letter on Q2 FY27 performance and missile-technology expansion. It cites a new ShauryAstra subsidiary for complete weapon systems.
Apollo Micro Systems Results Update
Apollo Micro Systems reported record Q2 FY27 standalone revenue of ₹306 Crore, up 97% quarter-on-quarter. H1 FY27 consolidated revenue rose 78% year-on-year to ₹639 Crore.
Apollo Micro Systems Investor Presentation: Key Takeaways
Apollo Micro Systems Q2 FY27 consolidated revenue ₹3,881.5 Mn (+72.3% YoY), EBITDA ₹1,111.8 Mn (+87.8%), PAT ₹461.5 Mn (+53.7%); H1 revenue ₹6,394.4 Mn (+78.2%). Strategy: Vision 2036 global OEM, explosives integration.
Apollo Micro Systems Q2 FY27 Results: Net Profit ₹46.2 Cr, Up 54.0% YoY
Apollo Micro Systems Ltd reported revenue from operations of ₹388.1 Cr (+72.3% YoY) and net profit of ₹46.2 Cr (+54.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹46.2 Cr · +54.0% YoY
Apollo Micro Systems Production Started
Group company IDL Explosives has commissioned its 9,000 MT Bolkunda Silo plant near Asansol. The facility expands IDL's bulk explosives delivery network in India's coal belts.
- bulk explosives silo capacity
- 9000 MT
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.